Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday ...

The first development that occurred is that it evaluated its drug tirzepatide (Zepbound) against Novo Nordisk (NVO) Wegovy (Semaglutide ... the phase 3 ACHEIVE-1 study using oral GLP-1 receptor ...

People in the study who were using Zepbound lost about 50% more weight those who got Wegovy, making it the superior drug in terms of weight loss. One curious thing about the study was that all the ...